Yazar "Buhur A." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Effect of etidronate on urinary Calcium/Creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study
    (1999) Kucuk S.; Gokdeniz R.; Atmaca R.; Uryan I.; Buhur A.; Taskin O.
    There are both histomorphometric and nonhistomorphometric studies confirming that etidronate reduces bone resorption. In this study, we have examined urinary Calcium/Creatinine ratio (uCa/Cr) as a biochemical marker of bone turnover to show the effectiveness of etidronate and whether it could be used as a follow-up parameter of treatment. Eighty-one postmenopausal women aged 40 to 65 included into the study to investigate the effects of etidronate on uCa/Cr in a prospective, randomised, placebo controlled clinical trial. All necessary criteria matched 81 women were divided into 3 groups at random, each group consisted of 27 patients. Prior to treatment, uCa/Cr was calculated from all subjects 3 hours after drinking 1 liter of water in the morning. Twenty seven (33.3%) women were randomised to oral doses of etidronate (400 mg/day for two weeks followed by drug free period of 10 weeks), twenty seven women to etidronate (400 mg/day for two weeks) plus calcium (1000 mg/day) for the following 10 weeks and twenty seven women to placebo (Fe, 50 mg/day) for 12 weeks. After 12 weeks of treatment, uCa/Cr declined significantly in the etidronate group from 0.118±0.064 to 0.053±0.021, in etidronate+calcium group from 0.08±0.03 to 0.06±0.015 ((p=0.004) and (p=0.005), respectively). In the placebo group no significant change was observed (p=0.03). In conclusion, etidronate is effective in postmenopausal women and the effectiveness of treatment may be followed up by measuring uCa/Cr which is a simple and cheap parameter of determining the effectiveness of etidronate in prevention of osteoporosis. However, since there are contradictory findings concerning uCa/Cr exist, larger clinical and prospective studies should be carried out.
  • Küçük Resim Yok
    Öğe
    Therapeutic effect of diasmin-hesperidin in primary dysmenorrhea
    (1997) Kafkasli A.; Buhur A.; Burak F.; Taskin O.
    Objective: To evaluate the effect of Flavinoid fraction; 450 mg Diasmin + 50 mg Hesperidin (DH), a venotrophic drug, in the treatment of the primary dysmenorrhea. Study Design: Thirty women, presenting with moderate (6 of 30, 20%) or severe (24 of 30, 80%) primary dysmenorrhea, were randomly divided into 2 groups. Each group received either DH tid or placebo for three months immediately after the onset of the menstrual flow and then each group was switched to the other regimen for the following three months. Ten point visual analogue scale was used to measure the pain of the patients. Statistical analysis was carried out by using student's t test, and chi square-test. Results: Pain scores were similiar in the placebo and the DH treated groups before treatment (7.5 ± 0.7 and 8.1 ± 0.2 respectively). Pain scores began to decrease one-hour following the DH administration and reduced to the lowest point at the third hour (from 5.5 ± 0.9 to 3.4 ± 0.9, p < 0.05). Satisfactory pain relief was detected in 90% of the patients. Meanwhile, pain scores in the placebo group did not change (7.8 ± 0.1 versus 7.6 ± 0.2, p > 0.05). The severity of the pain returned to pretreatment levels when the patients were switched to placebo. Conclusion: DH may be an effective drug for the treatment of primary dysmenorrhea in patients who can not use nonsteroidal anti-inflammatory drugs.